MedTrace Logo

Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection

NCT00304356 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-12-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.

Conditions

  • Clostridium Enterocolitis
  • Pseudomembranous Colitis

Interventions

DRUG

Nitazoxanide

500 mg bid

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • Daniel M. Musher MD

    lead FED

Principal Investigators

  • Daniel M Musher, M.D. · Baylor College of Medicine, Houston VA Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304356 on ClinicalTrials.gov